Selling, General, and Administrative Costs: GSK plc vs Dynavax Technologies Corporation

A Comparative Analysis of SG&A Expenses: GSK plc vs Dynavax Technologies Corporation

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Dynavax Technologies Corporation from 2014 to 2023. Over this period, GSK plc consistently reported SG&A expenses that were approximately 100 times higher than those of Dynavax, reflecting its expansive global operations and market reach. Notably, Dynavax's SG&A expenses surged by over 760% from 2014 to 2023, indicating significant growth and investment in its operational capabilities. In contrast, GSK's expenses remained relatively stable, with a slight dip in 2022. This stability underscores GSK's established market position and efficient cost management. As the pharmaceutical landscape continues to shift, these financial insights offer a glimpse into the strategic priorities and growth trajectories of these two distinct entities.